Sona Nanotech Inc. named Dr. Carman Giacomantonio, MD, MSc., FRCSC, to its Advisory Board. Dr. Giacomantonio is a surgical oncologist and professor of surgery whose research focuses on the mechanism of action of interleukin-2 therapy in the treatment of melanoma and breast and colorectal cancer. Dr. Giacomantonio is the principal investigator for the Company's current pre-clinical efficacy study at Dalhousie University.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.41 CAD | -2.38% | -2.38% | +70.83% |
Apr. 12 | Sona Nanotech Provides Interim Results of Dalhousie Study | MT |
Apr. 12 | Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study | CI |
1st Jan change | Capi. | |
---|---|---|
+70.83% | 29.69M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- SONA Stock
- News Sona Nanotech Inc.
- Sona Nanotech Inc. Appoints Dr. Carman Giacomantonio to its Advisory Board